Expert Consensus
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Dec 21, 2021; 27(47): 8069-8080
Published online Dec 21, 2021. doi: 10.3748/wjg.v27.i47.8069
Chinese expert consensus on neoadjuvant and conversion therapies for hepatocellular carcinoma
Hai-Tao Zhao, Jian-Qiang Cai
Hai-Tao Zhao, Department of Hepatobiliary Surgery, Peking Union Medical College Hospital, Beijing 100021, China
Jian-Qiang Cai, Department of Hepatobiliary Surgery, Cancer Hospital Chinese Academy of Medical Sciences, Beijing 100021, China
Author contributions: Zhao HT was responsible for investigation, writing-original draft, reviewing, and editing; Cai JQ was responsible for conceptualization, supervision, and writing-review and editing; all authors have read and approve the final manuscript.
Conflict-of-interest statement: The author has nothing to disclose.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jian-Qiang Cai, MD, Professor, Department of Hepatobiliary Surgery, Cancer Hospital Chinese Academy of Medical Sciences, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021, China. caijianqiang2021@163.com
Received: September 16, 2021
Peer-review started: September 16, 2021
First decision: October 16, 2021
Revised: October 27, 2021
Accepted: December 8, 2021
Article in press: December 8, 2021
Published online: December 21, 2021
Core Tip

Core Tip: Recent studies showed that neoadjuvant therapy for resectable hepatocellular carcinoma and conversion therapy for unresectable hepatocellular carcinoma are safe, feasible, and effective. It was necessary to conduct a widely accepted consensus among the experts in China who have extensive expertise and experience in treating hepatocellular carcinoma using neoadjuvant and conversion therapies.